Back in December last year, the Food and Drug Administration (FDA) approved clinical trials of MDMA therapy in America. As the major substance authority in the country, it was a huge, necessary hurdle for the drug to vault, and new reports have shown that the FDA are very happy indeed. Maybe it’s just the molly.
In a new report from the Multidisciplinary Association for Psychedelic Studies (MAPS), they revealed that the FDA have classified MDMA administration for patients suffering from post traumatic stress disorder (PTSD) as a “breakthrough therapy”.
Initial clinical trials for MDMA therapy in America have been a success, with the country’s largest drug authority marking it a “breakthrough” treatment.
For those who aren’t aware, MDMA is the active ingredient in ecstasy, and a banned substance pretty much everywhere. It’s legalisation as a treatment is following a similar path to marijuana, albeit a few years back on the timeline.
What this latest news means is that MDMA therapy will now enter Phase 3 trials; cutting-edge, randomised, double-blind, placebo-controlled research projects involving multiple teams.
All signs point to the drug being clinically available by 2021, possibly earlier.